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THE REGULATION OF DCDC2, A CANDIDATE GENE FOR DYSLEXIA 
Christopher J Gibson and Jeffrey R. Gruen.  Departments of Pediatrics, Genetics, and 
Investigative Medicine, Yale University School of Medicine, New Haven, CT. 
 
Within the human genome, genetic mapping studies have identified ten regions of 
different chromosomes, known as DYX loci, in genetic linkage with dyslexia.  The gene 
DCDC2, located within the DYX2 region on chromosome 6p22, has been shown to have 
genetic association with dyslexia in several independent studies.  Functional assays of 
DCDC2 indicate that it may help guide the migration of neurons during early brain 
development.  DCDC2 polymorphisms that display the strongest association with 
dyslexia are located in a highly GC-rich region in intron 2 known as BV677278. These 
polymorphisms contain several transcription factor binding sites, including the canonical 
8-base recognition site for PEA3, a transcription factor known to modulate neuronal 
migration in mice.  We hypothesized that 1) BV677278 is an enhancer element for 
DCDC2 that regulates its expression level, location, or timing, and that 2) PEA3 regulates 
DCDC2 expression by binding BV677278.  To test these hypotheses we showed that 
PEA3 binds to regions within BV677278, and that siRNA knockdown of PEA3 appears to 
delay the expression of DCDC2 during neuronal differentiation of mouse cells.  We 
concluded that PEA3 was a viable candidate transcription factor for DCDC2, with the 
ability to bind BV677278.  Taken together, these data suggest a possible mechanism by 
which BV677278 polymorphisms alter PEA3 binding and DCDC2 expression, which in 
turn may modulate neuronal migration and affect the risk of dyslexia. 
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Introduction 
Reading Disability (RD, also known as developmental dyslexia), is the most common 
learning disability among school-age children, with an incidence between 5% and 17% in 
countries where it has been studied.  It is defined as difficulty learning to read despite 
normal intelligence and adequate instruction.  The idea that differences in language and 
reading abilities are partially attributable to genetics is not new; as early as the 19th 
century, for instance, educators and physicians described families in which more than one 
member had difficulty learning to read.1  With the evolution of more sophisticated 
techniques of genetic analysis, our understanding of the biologic basis of these language 
disorders continues to grow.  This introduction summarizes some of the current 
understanding of the genes and proteins that are thought to affect RD.  The remainder of 
the paper describes experiments conducted to elucidate the regulation of DCDC2, a 
particular candidate gene for the disease.   
 
I. The Process of Identifying Language Disorder Genes 
To understand how the genes for language disorders are identified, one must first 
understand the types of studies geneticists utilize.  These can be visualized as a multi-step 
process of increasingly narrow scope, starting with heritability studies, proceeding to 
genetic linkage analysis and high-resolution genetic association studies (a process termed 
“positional cloning”2), and ending with functional assays of candidate genes.  In specific 
cases, other techniques, such as classical karyotyping, may also be used. 
 The simple observation that a trait runs in families is not enough to establish that 
it is genetic, since family members often share the same environment, and some of the 
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same genes.  The most common method used to confirm that a familial trait is at least 
partly heritable is a twin study, in which the concordance of the trait in monozygotic 
twins, who are genetically identical, is compared to its concordance in dizygotic twins (or 
any pair of non-twin siblings), who are not.3  A significantly higher concordance in 
monozygotic twins than in dizygotic twins implies that the trait has a genetic component.  
Statistical analysis can estimate the degree of phenotypic variation that is due solely to 
additive genetic factors, which is known as the trait’s heritability.4  For RD, twin studies 
have shown a heritability of 44% to 77%,5 implying that at least half of the entire range 
of disease can be attributed to genetic, rather than environmental, factors.   
 Sometimes, the next level of genetic study may be karyotype analysis, which has 
been used since the 1950s.  It involves light microscopic analysis of peripheral white 
blood cell chromosomes arrested in metaphase, and stained with giemsa to distinguish 
characteristic banding patterns for each chromosome.  Classical karyotype analysis can 
detect chromosomal deletions or duplications, as well as the exchange of large 
chromosomal segments, called translocations, on the order of 10 million bases (Mb). 
With higher resolution labeling, such as that used in Fluorescence In Situ Hybridization 
(FISH), smaller chromosomal abnormalities on the order of 100 kb can be identified.  
Although karyotype analysis is sometimes used in clinical genetics, its use is 
often limited, and it is not commonly used in large research studies.  This is due in part to 
its inability to analyze sequence and DNA microstructure.  The presence of regulatory 
elements, epigenetic modification, and diverse gene-gene interactions, which affect gene 
penetrance and the heterogeneity of expression, often mean that siblings who possess 
identical chromosomal macrostructure may nevertheless display different phenotypes.  
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Nevertheless, we mention karyotyping here because two of the four RD genes, DYX1C1 
and ROBO1, were identified through the serendipitous discovery of chromosomal 
translocations by karyotype analysis. We will detail its application when we discuss the 
specific genes below. 
 Traditionally, once a trait or disease has been shown to have a genetic component, 
the next step has been genetic linkage analysis, which determines the chromosomal 
regions, usually 1-20 Mb in size, that contribute to the development of the trait.6  In 
performing these studies, researchers compare genotypes from multiple members across 
several generations of families affected by the trait in question and consider markers 
distributed across all chromosomes.  Although older studies utilized microsatellites or 
short tandem repeats (STRs), the markers most commonly used in modern genetic studies 
are Single Nucleotide Polymorphisms (SNPs), variations in single bases that occur on the 
order of one per 100 bases of DNA.7  Traditionally, by tracing the lineage of marker 
alleles across generations and comparing it with the lineage of the trait in the family, 
researchers have identified markers within a specific chromosomal region that are 
inherited in the same pattern as the trait.  These markers are said to be “in genetic 
linkage” with the trait because the marker and trait appear together more often than 
would be expected by chance alone (that is, they are physically “linked” by their 
proximity on a chromosome and cosegregate during recombination events in meiosis); 
the chromosomal region in which they are encoded is termed a “susceptibility locus.”   
Classical linkage analysis using large pedigrees is best suited to Mendelian 
diseases.  More recently, researchers have developed models that determine linkage by 
comparing the rate of allele sharing in sibling pairs (or other relational groupings) to the 
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rate of sharing predicted by chance alone.  This method eliminates the need to obtain 
DNA from multiple generations, which is often difficult to accomplish and has 
traditionally been a barrier to efficient linkage studies.8  Perhaps more importantly, it 
allows for analysis of complex diseases because it de-emphasizes the mode of disease 
inheritance, which for complex diseases is never well defined.  
 Numerous linkage studies have been performed for RD and have identified about  
ten susceptibility loci, which are collectively designated by the label DYX.  The evidence 
supporting the involvement of some of these loci in RD is relatively weak, but four have 
been consistently replicated: DYX1 on 15q9, 10, DYX2 on 6p11, DYX5 on 3p12, and 
DYX6 on 18p13.  These regions may encode genes that affect heritable susceptibility to 
RD across the general population, while the other six loci likely encode genes with RD 
polymorphisms unique to small populations.  It is also likely that other loci affecting 
reading and RD exist in the genome but have not yet been discovered. 
 After a linkage study has implicated a chromosomal region in the development of 
a disease, the next step has traditionally been to identify candidate genes using genetic 
association studies, which compare the frequency of marker alleles in affected subjects 
(cases) to the frequency in matched unaffected controls.  The premise of these studies is 
that, due to historical recombination events over many generations, marker alleles found 
significantly more often in affected individuals must be in close physical proximity to the 
disease-causing mutation.  Genetic linkage analysis are powerful and can sensitively 
determine the location of a disease-related gene to within 5 to 10 million base pairs, but 
their poor resolution precludes them from more finely localizing disease-related genes.  
Association analysis, on the other hand, can be much more precise.  Its major weakness is 
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that it is vulnerable to false-positive association due to hidden population stratification 
(that is, occult allele sharing between cases and controls as a result of ancient admixture) 
when unrelated cases and controls are matched.  Thus most widely-used association tests 
employ a family-based structure in which the cases and controls are not individuals but 
genotypes; the parental genotype found in the affected individual serves as the case, and 
the untransmitted parental genotype is the control.  Using an array of finely spaced 
markers in a family-based association study, researchers can pinpoint a peak of 
association within a locus previously identified by a linkage study with both precision 
and relative certainty. 
 The need to perform a linkage study before testing association can be eliminated 
if the entire genome, as opposed to a single susceptibility locus, is interrogated by genetic 
association for disease-associated marker alleles. The advent of gene-chip technology, in 
which more than one million markers spanning the genome can be tested for association 
with a trait or disease, has made such genome-wide association (GWA) studies possible. 
Several well-publicized GWA studies have already been performed for common complex 
disorders (due to a combination of multiple genes and environmental factors), such as 
coronary artery disease,14 breast cancer,15 Type 2 Diabetes,16 and multiple sclerosis.17  
The major drawback to GWA studies is the large number of markers needed to cover the 
genome, which greatly increases the likelihood of false-positive associations due to 
multiple testing.  For complex diseases, in which the effect size may be small, the need to 
control for multiple testing requires the recruitment of several thousand case subjects and 
at least as many controls, making GWA studies  expensive and complicated, and 
effectively impossible for rare diseases.18  
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II. Candidate Genes for Reading Disability: Discovery and Functional Assays 
The methods described above have resulted in the identification of four candidate genes 
for dyslexia: DYX1C1 in DYX1,19 DCDC220  and KIAA031921 in DYX2, and ROBO1 in 
DYX5.22  Three of these are discussed here; DCDC2, the subject of this study, is 
discussed in section III. 
Once candidate genes have been identified by genetic association studies, a 
common step in elucidating the pathway through which they contribute to the disease is 
the determination of their physiologic function. The disease variants of the gene, whether 
full translocations or smaller sequence variations, can then be evaluated in the context of 
the gene’s function to understand how they confer disease susceptibility.  In the case of 
RD, three genes (DCDC2, KIAA0319, and DYX1C1) appear to influence the migration of 
developing neurons during early embryogenesis, while ROBO1 appears to affect the 
extension of axons from neuron cell bodies.  As above, discussion of DCDC2 is reserved 
for section III. 
 
KIAA0319 
In 2005, Cope et al identified KIAA0319, located on 6p21, by interrogating 5.3 million 
bases (Mb) spanning the region with 57 SNPs, in a sample of 143 parent-proband RD 
trios in the United Kingdom.21  The study found association not within the gene itself, but 
in a region immediately adjacent to the gene’s transcription start site. These regions, 
called 5’ untranslated regions (5’ UTRs), often regulate the timing and degree of 
transcription. In this case, the SNPs associated with the development of RD appeared to 
decrease the transcription of KIAA0319. The results of the initial association study for 
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KIAA0319 have been replicated in two further studies, one in a cohort from Wales23 and 
one in a cohort from the United States.24  However, a more recent study in a large 
population failed to show the same degree of association.25 
KIAA0319 mRNA transcripts are present at very high levels within the human 
brain, particularly in the visual and parietal cortices.  RNAi knockdown studies of 
KIAA0319 have resulted in aberrant migration of affected neurons, though in a pattern 
different from that of DCDC2 knockdown.26 The molecular mechanism by which 
KIAA0319 exerts its neurostructural effects has not yet been elucidated, though recent 
studies have shown that the full protein product of the gene resides in the plasma 
membrane of neurons and may mediate interactions between these and the supporting 
cells of the brain, known as glial cells. 27 
 
DYX1C1 
As previously mentioned, DYX1C1 (originally called EKN1) was initially discovered by 
karyotype analysis,  which showed a translocation segregating with RD in a family in 
Finland.12  In this case, the q11 portion of chromosome 15, which had already been 
identified by linkage analysis and designated DYX1, was translocated onto chromosome 
2, and the q21 portion of chromosome 2 was translocated onto chromosome 15 (notated 
t(2;15)(q11;q21)); analysis of the exact position of the chromosome 15 breakpoint 
showed that it lay within a gene called EKN1.  A small genetic study of families in 
Finland showed association with EKN1/DYX1C1,19 as did a study in Canada,10 but studies 
in the United States28 and Italy29 failed to show an association. This implies that the 
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importance of DYX1C1 as a susceptibility gene for RD may be limited to specific 
populations. 
Like KIAA0319, DYX1C1 has been shown to be highly expressed in brain.19 
Furthermore, RNAi knockdown of DYX1C1 significantly impaired neuronal migration, 
implying that it likely plays a role in early brain development.30  
 
ROBO1 
Similar to DYX1C1, ROBO1 was first identified by finding a translocation in an RD 
family31 through karyotype analysis. In this case, the translocation was between the p12 
region of chromosome 3 and the q11 region of chromosome 8 (t(3;8)(p12;q11)). Since 
3p12 had already been identified as DYX5 in a previous linkage study, an association 
study using SNPs was conducted on the original linkage cohort, which showed an 
association between certain SNPs within ROBO1 and decreased expression of the gene.22 
However, there has not yet been independent validation of this gene in a separate RD 
cohort. 
As opposed to the other three RD susceptibility genes, ROBO1 does not appear to 
affect neuronal migration. Rather, it has been shown to encode an axonal guidance 
receptor, that is, a protein involved in receiving cellular signals to help direct the 
projection of axons from the neuron cell body.22  In the absence of strong evidence for 
genetic association, understanding the molecular role of the ROBO1 protein product lends 
some credibility to assertions of its role in reading. 
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III.  The identification, function, and regulation of DCDC2 
Meng et al first identified DCDC2 as a candidate gene for dyslexia in 2005 in a genetic 
association study of 220 RD families from Colorado,20 which was confirmed by 
Schumacher et al in a different German cohort shortly thereafter.32  In the initial study, 
Meng et al examined 149 SNPs over 1.2 Mb of 6p22 and found a peak of association in 
six non-coding SNPs within an intron of DCDC2.  Since introns are spliced out of the 
RNA transcript and do not affect the sequence of the ultimate protein product, these 
results imply that the susceptibility polymorphisms for DCDC2 occur in a regulatory 
region of the gene.  In other words, the known polymorphisms do not affect the amino 
acid sequence of the DCDC2 protein product, but rather affect where (e.g., specific brain 
region or type of neuron), when (e.g., during a specific period of brain development), or 
how much of the protein is produced.  
 Meng et al surveyed levels of DCDC2 messenger RNA (mRNA) levels and 
showed that it is expressed in the brain, especially in the temporal cortex and cingular 
gyrus, regions known to be involved in reading.  They also performed functional studies 
of the gene, which implied that it may be necessary for the proper migration of neurons 
from the region around the brain ventricles, where they originate during early 
embryogenesis, to the outermost layer of the cerebral cortex, where they reside in 
maturity.  In these studies, called RNAi knockdown assays, DCDC2 mRNA in 
embryonic rat brain was specifically prevented from being translated into protein in early 
neural progenitor cells.  Cells with decreased DCDC2 levels stopped migrating at 
intermediate areas of the cerebrum, whereas wildtype cells expressing normal amounts of 
DCDC2 migrated to the outer layers of the cortex. 
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At a molecular level, DCDC2’s effect on neuronal migration may occur via 
interactions between the DCDC2 protein product and the cellular scaffolding known as 
the cytoskeleton.  One of the functional domains of the DCDC2 protein product, known 
as the doublecortin domain, has been shown in other studies to stabilize the assembly of 
important cytoskeletal components called microtubules.33  If this proposed pathway is 
correct, decreased levels of the DCDC2 protein product caused by dyslexia-associated 
polymorphisms may confer disease susceptibility by destabilizing microtubule structures 
and impairing the ability of neurons to migrate through the developing brain.  
 It is difficult, however, to reconcile the results of these functional studies with the 
observation that the polymorphisms identified within DCDC2 all lie within the intronic 
region BV677278.  Since this region is not translated into protein, it is unlikely that RD-
related polymorphisms of DCDC2 directly affect the gene’s protein product.  Instead, it is 
most likely that the RD-related polymorphisms alter a critical sequence necessary for the 
binding of an important transcription factor (TF).  Indeed, reporter assays of BV677278 
have suggested that it may have just such a function (Meng et al 2006, unpublished data).  
When the region was cloned into an expression vector downstream (3’) of firefly 
luciferase gene, the light emitted by human Jurkat cells transfected with the vector 
increased compared to control (vectors containing firefly luciferase but without 
BV677278).  When BV677278 was inserted upstream (5’) of the luciferase gene, 
however, there was no significant difference in light production compared to control 
cells.  This suggests that BV677278 may act as a distal regulatory element, or “enhancer,” 
rather than as a proximal regulatory element, or “promoter.”  Whereas promoters are 
regions of DNA at which transcription initiation complexes bind (and are thus essential to 
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the successful transcription of genes), enhancers serve as binding sites for transcription 
factors that may finely modulate, rather than switch on or off, gene transcription.      
These results thus suggest that BV677278 may act as an enhancer at which a 
critical transcription factor binds DCDC2.  This TF may modulate the production of the 
DCDC2 protein product, or it may affect the product of another nearby gene, such as 
KIAA0319, which, as previously noted, lies in the same 500 Kb locus as DCDC2.  The 
existence of such a relationship, in fact, could reconcile the apparent coincidence that two 
genes showing independent association within RD lie in such close proximity to each 
other.  Figure 1, shown on the following page, details possible mechanisms by which 
such a regulatory element could ultimately influence the development of neural 
architecture and a complex cognitive phenotype such as reading. 
  
 
  
 
 
Figure 1. A: The DYX2 locus on 6p22 contains two candidate dyslexia genes, DCDC2 and KIAA0319, within a 500 Kb span.  B: BV677278, an 
approximately 600-bp region in intron 2 of DCDC2, has been shown by luciferase assay to have enchancer activity.  C. One possible scenario by which 
both DCDC2 and KIAA0319 might contribute to dyslexia: if protein products of both genes are involved in reading, then risk polymorphisms in either 
could directly influence disease development. D. An alternative explanation might be that a transcription factor binds at an enhancer within one gene 
(e.g. BV677278 in DCDC2) and regulates the expression of the other.  The altered expression of the latter protein product is therefore responsible for the 
development of disease. 
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Figure 2. Comparison of neural migration defect conferred by 
knockdown of DCDC2 or dominant negative of PEA3.  In 
wildtype rats, Meng et al (2005) showed that the majority of 
normal neural progenitors, labeled green, migrate to the outer 
layers of the cerebral cortex (A).  DCDC2 knockdown cells 
(B) arrested predominantly in the intermediate zone.  
Hasegawa et al (2004) showed a similar population of neural 
progenitors reaching the outer cortex (CP) in wildtype mice 
(C).  Neurons transfected with a PEA3 dominant negative 
construct (D) cluster overwhelmingly in the intermediate zone.
 
If there is a TF that binds BV677278, 
which one is it and how exactly does 
it exert its effects?  One particularly 
interesting candidate is PEA3 (whose 
identification is described in 
Methods, below), a member of the 
ETS family of transcription factors  
expressed in human neocortex.  In 
2005, Hasegawa et al showed that 
PEA3 expression is dependent on the 
activation of fibroblast growth factor 
receptors (FGFRs), and that neurons 
with dominant negative mutations of 
PEA3 display an aberrant migration 
pattern when implanted in developing 
mouse brains in a pattern of intermediate-zone arrest identical to that of the DCDC2 
knockdowns described by Meng in 2005.34  Figure 2, above, compares the migration 
deficit shown by these two papers. 
Two questions must be answered to say with confidence that PEA3 is in fact a 
critical transcription factor for either DCDC2 or KIAA0319.  First, can PEA3 bind to 
BV677278?  Second, does changing the expression of PEA3 (in this case, knocking it 
down completely) affect the expression of either DCDC2 or KIAA0319?  The answer to 
these questions is the subject of the experiments described here. 
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Hypothesis and Specific Aims 
Based on the background presented here, we hypothesized that the intronic region 
BV677278 within DCDC2 is a critical regulatory region for DCDC2 or KIAA0319.  To 
test this hypothesis, we proposed: 
 
Specific Aim 1: Using a bioinformatics approach, identify viable candidate transcription 
factor(s) based on binding properties, tissue localization, and known function; 
 
Specific Aim 2: Test the candidate transcription factor(s) for binding to BV677278 using 
electrophoretic mobility shift assays; and 
 
Specific Aim 3: Characterize the regulatory effect of the candidate transcription factor(s) 
on DCDC2 and KIAA0319, two proposed dyslexia genes, using siRNA knockdown of 
PEA3 and quantitative rt-PCR assays of gene expression.    
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Methods 
Statement of Medical Student Contribution  
The bioinformatics approach to transcription factor discovery, and the initial supershift 
assays, were conceived by Haiying Meng in the Gruen lab.  The author refined the 
bioinformatics search and conceptualized the final design of the supershift assays.  All 
other project design was conceived  by the author.  The author solely performed all 
experiments and analysis, wrote all text, and designed all figures, except for Figure 2 in 
the Introduction, which as noted presents previously published data from papers by Meng 
et al 2005 and Hasegawa et al 2004. 
 
Identification of Candidate Transcription Factors 
Four oligonucleotide sequences, each 22 nucleotides in length, were identified within 
BV677278.  Each of these was shown to be altered or obliterated by the insertion or 
deletion of the short tandem repeats associated with RD.  These four probes 
(TAAAAAGAAGGAAAGAGAGG, GAGAGGAAGGAAAGAGAGGA, 
GAGAGGAAGGAAAGGAAGGA, AAGGAAGGAAGGAAAGAATG), were each 
queried in the Transcription Element Search Software database (TESS, University of 
Pennsylvania) for all known transcription factor binding sites lying within them. 
 
Cell Culture and Neural Differentiation 
P19 (mouse teratocarcinoma) cells were obtained from ATCC (Manassas, Virginia).  
These were cultured in α-MEM supplemented with 7.5% fetal bovine serum, 2.5% calf 
serum, 5 ml 1x glutamine and 5 ml penicillin-streptomycin and split 1/8 every other day 
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with TrypLE (proprietary trypsin formulation, Invitrogen, Carlsbad, CA).  Mouse 
embryonic stem cells containing GFP in the Sox1 promoter (referred to as “Sox1GFP 
cells”) were originally engineered by the Smith lab, Cambridge, UK, and were obtained 
as a generous gift from Professor Laura Grabel, Wesleyan University.  These were 
cultured in Glasgow-MEM supplemented with 10% FBS (lot-tested), 1% 1x glutamine, 
1% penicillin-streptomycin, 1% non-essential amino acids, 1% sodium pyruvate, 3. 5 µl 
Β-mercaptoethanol, and 0.2% leukocyte inhibitory factor (LIF).  Passaging was the same 
as for P19s. 
 The differentiation of P19s into neural-like cells has previously been described in 
detail.35  Briefly, after trypsinization, cells were plated into 6-well trays at a density of 1 
to 3 x 105 cells/well in P19 growth medium supplemented with 5 x 10-7 M all-trans-
retinoic acid (atRA).  This medium was changed daily until differentiation day 4, when it 
was replaced by normal P19 growth medium to minimize atRA toxicity.  Cells were 
trypsinized and replated when they reached 100% confluency, with complete 
differentiation lasting six to eight days. 
 The differentiation of mouse embryonic stem cells into neuronal precursors has 
also been described in detail elsewhere.36  Briefly, Sox1GFP cells were plated 1 x 105 
cells/well in serum-free medium supplemented with B27 (Invitrogen; lot-tested) and N2 
(progesterone, insulin-transferrin-selenium, and putrescine).  This medium was changed 
daily.  Full differentiation took twelve days, and cells were generally split and replated at 
day 7-8.      
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RNA Extraction 
RNA extraction was performed using RNEasy Plus© kits from Qiagen.  Briefly, cells 
were trypsinized, then homogenized in QiaShredder homogenizer columns.  The rest of 
the extraction was performed according to the RNEasy protocol.  RNA concentration was 
assayed by assessing absorbance at 260 and 280 nm. 
 
RT-PCR 
Prior to PCR, 1 µg RNA from each sample was reverse transcribed into cDNA using an 
archive kit based on random primers (ABI).  Quantitative RT-PCR was performed with 
the Taqman® system from ABI using 48-well plates.  Reactions were all performed 
either in duplicate or triplicate.  Fluorescent primers used (all mouse) were dcdc2a (the 
full-length transcript of mouse dcdc2), d130043k22rik (mouse ortholog of KIAA0319; 
hereafter referred to as kiaa0319), pea3, sox1, and mtap2.  Mouse gadph was used as an 
internal control. 
 
Electrophoretic Mobility Shift Assays (EMSAs) 
These were performed using the Lightshift® kit (ThermoFisher Scientific, Rockford IL).  
The four DNA oligonucleotides (hereafter Probes 1-4) from within BV677278 were 
annealed and labeled with biotin.  They were then incubated with human brain nuclear 
lysate under varying reaction conditions.  For each experiment, at least three reaction 
mixtures were incubated: one containing labeled probe only (the baseline mixture), one 
containing labeled probe plus brain lysate (the experimental mixture), and one containing 
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labeled probe, brain lysate, and an excess of unlabeled probe, to test the specificity of 
binding between probe and lysate.   
 After incubation, the reaction mixtures were loaded into a native (non-denaturing) 
4% polyacrylamide gel and run at 80 V for 2 hours at 4 degrees Celsius.  The protein was 
then electrophoretically transferred to a positively charged nylon membrane at 400 mA 
for 30 minutes, and crosslinked to the membrane using ultraviolet radiation in a UV 
Spectralinker (Stratagene).  The blocking, hybridization, and washing steps were 
performed using provided Lightshift products; the hybridization was to a strepavidin-
horseradish peroxidase conjugate.  Membranes were developed using ECL and exposed 
to x-ray film for two minutes.  
 
Supershift Assays 
These were performed similarly to EMSAs, as described above, except that during 
incubation, mouse monoclonal or rabbit polyclonal anti-PEA3 (Santa Cruz, sc-113 or 
H120) was added to the reaction mixture.  For each experiment, one additional reaction 
mixture substituting mouse anti-IgG, goat anti-DCDC2, or mouse anti-Oct2A was 
incubated as a control. 
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Results 
Identification of Candidate Transcription Factors 
The four oligonucleotides identified as the critical regions of BV677278 for dyslexia risk 
were each entered into the TESS database.  The queries showed that each probe 
contained binding sites for about twenty transcription factors, but only two, PEA3 
(consensus sequence: AGGAAR, where R = purine) and NF-1 (Nuclear Factor-1, 
consensus sequence: TGGCA ) are expressed in human brain.  The expression of NF-1 is 
ubiquitous, but little is known about its function in humans, and it has mostly been 
characterized in adenovirus, where it was discovered.37  PEA3 is expressed strongly in 
human brain.38  The full results of the search are shown in Appendix 1. 
 
Supershift Assays 
To determine whether the transcription factor PEA3 can bind in vitro to BV677278,  
supershift assays were performed using labeled DNA probes and human brain nuclear 
lysate.  The results are displayed in Figure 3, below.  In lane 1, labeled probe alone 
migrated to the bottom of a native polyacrylamide gel, marked by arrow B.  When 
incubated only with brain lysate (lane 2, marked with upward pointing arrow), the 
original band was greatly reduced and a new band appeared at the top of the gel, marked 
by arrow A, indicating a binding reaction between the probe and some component of the 
lysate mixture.  When labeled probe was incubated with both lysate and non-specific 
antibody (anti-Oct2A, lane 3), the appearance of the lane was similar to that of lane 2 (no 
band at arrow B). 
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 Lanes 4 through 7 show the effects of adding increasing amounts of monoclonal 
anti-PEA3 antibody.  A band in the region of unbound probe (arrow B) becomes 
increasingly prominent as the concentration of antibody is incrementally increased, 
indicating that the antibody and probe compete for binding to the unknown component of 
brain lysate.  A similar band with the addition of specific, unlabeled probe is seen in lane 
8.  Adding both monoclonal anti-PEA3 and an excess of unlabeled specific probe 
produces a band more intense than the addition of either species alone (lane 9).  Finally, 
incubation of labeled probe and lysate with a non-specific competitor DNA (Epstein Barr 
Nuclear Antigen DNA) failed to produce a competitive band in the region of arrow B.  
 
Figure 3. Electrophoretic Mobility Shift Assay testing interaction between probes from BV677278 and 
PEA3.  In lane 1, labeled probe alone migrated to the bottom of the gel (arrow B).  When probe was 
incubated with human brain lysate, lane 2, a band appeared at the top of the gel (arrow A), indicating 
binding between probe and lysate (known as “shift” ).  Incubation of labeled probe and lysate with PEA3-
specific antibody produced a competitive band (arrow B) that increased in intensity as the concentration of 
antibody increased (lanes 4-7).  Incubation of labeled probe and lysate with either non-specific antibody 
(anti-Oct2a, lane 3) or non-specific probe (EBNA DNA, lane 10) failed to produce a similar band.   
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Quantitative RT-PCR 
To avoid confusion, the following conventions of terminology apply: “wildtype” refers to 
cells that were not transfected with anti-pea3 siRNA, whereas “naïve” refers to cells that 
were not treated with atRA (and thus not differentiated into neural-like cells). 
 P19 cells were treated with a 6-day course of 5 x 10-6  M all-trans-retinoic acid 
(atRA) to induce neural differentiation.  To determine whether cells had in fact 
committed to a neural genetic profile, qRT-PCR was used to determine the relative levels 
 
Figure 4. Expression of two neural markers, sox1 and mtap2, in P19 cells during exposure to all-trans-
retinoic acid, ±SEM.  The expression of both genes was initially low, but rose with increasing time of 
exposure. 
 
of sox1, a marker of early neural development, and mtap2, a marker of later neural 
development.  Results are shown in Figure 4, above.  The expression of sox1 began to 
rise at atRA day 3 and peaked at day 5, with a marked decrease by day 6.  The expression 
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of mtap2 followed essentially the same profile, though levels declined less between days 
5 and 6 than for SOX1. 
 qRT-PCR was then used to determine the relative expression of dcdc2a, 
kiaa0319, and pea3 in the same P19 cells.  The relative expression of each gene product 
was plotted against time treated with atRA to give a rough timeline of changes in  
 
Figure 5. Expression of dcdc2a and kiaa0319 during exposure to all-trans-retinoic-acid in P19 cells, 
±SEM.  Dcdc2a expression is initially low, then rises abruptly at day 2.  kiaa0319 expression is relatively 
stable until late in neural development.  Left y-axis: dcdc2a; right y-axis: kiaa0319. 
 
expression during neural differentiation.  The results of these experiments are shown in 
Figure 5, above.  In wildtype cells, the expression of dcdc2a was relatively low before the 
initiation of treatment with atRA; expression peaked at day 2 and returned to baseline 
levels by day 6.  Expression of kiaa0319 was also initially low in wildtype cells before 
the initiation of atRA, and then rose steadily, peaking at day 6.  The expression kiaa0319 
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was much higher than that of dcdc2; for purposes of graphical representation, different 
scales are represented on two y-axes. 
  
To determine the success of pea3 knockdown, relative pea3 mRNA expression  was 
plotted versus time for wildtype (non-transfected) and experimental (transfected with 
pea3 siRNA) P19 cells.  The results are shown in Figure 6, above.  In wildtype cells, 
pea3 expression was highest in the naïve state (not exposed to atRA), and then steadily 
declined with increasing exposure to atRA, consistent with assays of pea3 expression 
during mouse cell differentiation described by Xin et al.38  Knockdown of pea3 was 
successful in naïve cells and after one day of atRA treatment, but with longer exposure to 
Figure 6.  Expression of pea3 in P19 cells during exposure to all-trans-retinoic acid, ±SEM.  The light blue 
line represents pea3 expression in wildtype P19s, whereas the dark blue line represents expression in cells 
exposed to pea3 siRNA.  Knockdown of pea3 ceased to be effective at day 2. 
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atRA (two days and beyond), knockdown ceased to be effective.  This result was 
consistent across several repetitions of the experiment. 
 The expression of each gene in wildtype cells was then compared to the 
expression in cells that had been treated with anti-pea3 siRNA.  The results of these 
experiments are shown in Figures 7 (dcdc2a) and 8 (kiaa0319), below.  In naïve cells, 
expression of dcdc2a was significantly higher in pea3 knockdown cells than in wildtype 
cells.  
 
Figure 7. Change in dcdc2a expression with pea3 knockdown, ±SEM.  In wildtype P19 cells, dcdc2a 
surges after two days of treatment with all-trans-retinoic acid, then returns to baseline.  This surge is 
delayed until day 5 in P19 cells that have been transfected with anti-pea3 siRNA.  
 
On day 1 of neural differentiation, however, there was no significant difference in dcdc2a 
expression between wildtype and knockdown cells, even though the knockdown was 
successful.  On day 2 of differentiation, the expression of dcdc2a was significantly 
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different in the two populations of cells, but the expression of pea3 did not differ 
significantly (i.e. the knockdown was not successful). The expression of kiaa0319 was 
not significantly different between the two groups on any of these early days of 
differentiation.
 
Figure 8. Change in kiaa0319 expression with pea3 knockdown, ±SEM.  In wildtype P19 cells, kiaa0319 
remains at low baseline levels until after 2 days of treatment with all-trans-retinoic acid, when expression 
begins to increase.  There is no significant difference in expression when pea3 is knocked down. 
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Discussion 
Our understanding of the genetics underlying reading disability has improved greatly 
over the last century.  We have moved from a general observation that reading difficulties 
often appear to segregate in families to the identification of specific candidate genes 
postulated to exert effects on brain development.  Yet despite these advances, many 
questions remain.  Exactly what is the function of these genes at the molecular level?  
More broadly, how do these effects work together at the levels of brain structure, 
function, and development to influence such a complex phenotype as reading ability? 
 Crucial to answering these questions is an understanding of how the genes 
implicated in reading ability are regulated.  As our comprehension of genetics has 
improved, we have come to realize that many diseases are not simply the results of 
mutations affecting the structure of a gene product per se, but are rather due to subtle 
changes in where, when, or how much of the gene product is made.  This is certainly 
implied by polymorphisms identified in studies of RD.  In DCDC2 and KIAA0319, the 
two genes for which the most credible evidence of association with RD exists, candidate 
polymorphisms have only been identified in non-coding areas.  Sequence changes in 
these regions could then change the binding affinity of transcription factors, either 
increasing or diminishing their ability to affect transcription of a target gene.  
 We were particularly interested in whether BV677278, the highly polymorphic 
region in intron 2 of DCDC2 that is associated with RD, might harbor such a 
transcription factor binding site.  This study sought to identify which TF(s) might bind in 
this region, and to describe the effects any candidate TFs might have on the transcription 
of downstream gene targets, namely DCDC2 and KIAA0319. 
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 The rough pathway for discovery and verification of a transcription factor is 
shown in Figure 9, below.  Speaking generally, after identification of candidate TFs, each 
candidate must be tested for binding to the DNA sequence under investigation (the 
“probe”).  After a candidate has been shown to bind the target sequence, it must then be 
shown to affect the expression of the gene in question.  These were the criteria we 
decided any viable candidate TF must meet. 
 
Figure 9.  Hypothetical (left column) and actual (right column) algorithms for evaluating candidate 
transcription factors.  After an initial screen to find initial pool of candidates, each must be tested for its 
ability to bind the specific DNA sequence.  Once this has been shown, the TF must also be shown to affect 
the expression of target genes.  If either the EMSA or the siRNA studies of PEA3 had been unsuccessful, 
the appropriate next step would be to return to broad screen, such as a yeast one-hybrid. 
 
There are thousands of known transcription factors, so our first problem was 
finding a way to eliminate most of these and focus our investigation on a manageable 
number of candidates.  The classic method of identifying candidate transcription factors 
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is through an assay known as a yeast one-hybrid.  In this assay, a pre-determined library 
of transcription factors is screened for the ability to bind a particular DNA sequence.  
Only yeast clones in which a particular candidate TF stably binds this sequence will grow 
on selective media.  Unfortunately, the yeast one-hybrid often returns TFs that appear to 
bind the target region in the assay but do not display regulatory activity in vivo.39, 40  
Furthermore, it is a labor-intensive assay that often yields over ten candidates, all of 
which must be tested for appropriate in vivo behavior. 
 A less exhaustive but quicker method is a bioinformatics approach.41, 42  The 
Transcription Element Search Software (TESS) is an online database sponsored by the 
University of Pennsylvania that allows the input of DNA sequences and returns all 
known transcription factors with binding sites in the queried sequence.  BV677278 is over 
2 Kb long, and interrogating the entire sequence would likely yield an unacceptably high 
number of possible TFs.  Since it is comprised of compound short tandem repeats, 
however, we realized that there were only four small regions whose sequences were 
altered by the expansion or contraction of these repeats.  We reasoned that if BV677278 
indeed affects reading ability through the binding of transcription factors, those factors 
most likely bind in the areas that are disrupted by dyslexia-associated polymorphisms, so 
we felt confident using these four 22-nucleotide sequences as input for the TESS search. 
 The search returned a number of hits, but only two really viable possibilities.  
One, NF-1 (Nuclear Factor-1), is ubiquitously expressed in humans, but its role has so far 
mainly only been shown to be important in adenoviruses,37 so it seemed unlikely to be 
contributing to reading disability.  The other, PEA3, was intriguing. Most studies of 
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PEA3 so far have been focused on its role in cancer; it has been noted, for example, to be 
overexpressed in breast tumors.43   
 There is evidence, however, that PEA3 likely plays a role in neural development 
as well.  First, it is expressed at high levels in human brain, particularly in the 
telencephalon,44 where activities of higher cognition take place.  Second, there is 
evidence that it is specifically important in guiding neural precursor cells from their 
origin in the periventricular region of brain to their ultimate destination in the outer layers 
of the cerebral cortex.  In 2004, a Japanese group created a dominant negative mutation 
of PEA3 in mouse neuronal precursors by transfecting them with a vector that 
overexpressed only the DNA-binding portion of the protein, thereby blocking functional, 
wildtype PEA3.34  When labeled with a fluorescent marker and transplanted into the 
brains of developing mice in utero, the PEA3-mutant neuronal precursors did not migrate 
to the outer layers of the cortex, as they normally should have, but instead halted in the 
intermediate zone of the brain.  Their axonal projections displayed aberrant architecture 
as well. 
 This morphology is strikingly reminiscent of the aberrant migration pattern of 
DCDC2-knockdown cells when implanted into developing rat brain.  These experiments 
were conducted in cooperation between our lab and the LoTurco lab at the University of 
Connecticut and reported by Meng et al in 2005.  Although only a circumstantial 
observation, the similar laminar patterning in DCDC2 knockdowns and PEA3 dominant 
negatives raises the possibility that PEA3 may bind DCDC2 (or, perhaps, KIAA0319, 
which is nearby) and upregulate its expression.  When PEA3 function is ablated, as in the 
Japanese experiments, the resultant decrease in DCDC2 or KIAA0319 expression might 
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be similar to the decrease that results when the genes are knocked down directly, as in 
our experiments.  In either case, whatever effect the downstream gene product (i.e. 
protein) has on directing neuronal migration is abolished, resulting in an abnormal 
architectural phenotype. 
 Our hypothesis, prior to the experiments described here, was that first, PEA3 
could bind to BV677278, and second, that it affects the expression of DCDC2 or 
KIAA0319.  The results of the experiments appear to support both claims. 
 The first question—whether PEA3 can bind to BV677278—was approached by 
supershift assay, a two-step process.  The first step was simply to show that the 22-
nucleotide probes taken from BV677278 bind human brain nuclear lysate, which would 
by inference imply that the probes bind to some transcription factor found in human 
brain.  This result, known as “shift,” is evident by comparing lanes 1 and 2 of figure 2.  
The naked probe, labeled with horseradish peroxidase, quickly migrated to the bottom of 
the native polyacrylamide gel during electrophoresis.  When nuclear lysate was added, 
the probe’s mobility was greatly retarded, and the dominant band appeared near the top 
of the gel.45, 46  Our results consistently showed strong shift for all four 22-nt probes, 
indicating that these sections of BV677278 indeed bind a transcription factor found in 
human brain. 
 The second step of the assay—the “supershift” portion—was designed to identify 
the specific transcription factor in the soup of lysate that caused the change in mobility of 
the labeled probe during the shift assay.  In this step, an antibody to PEA3 was incubated 
in the same reaction mixture as the labeled probe and the lysate.  The idea here was that if 
PEA3 is the actual transcription factor causing the original shift, the interaction of the 
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antibody and PEA3 will further change the mobility of the entire complex, though the 
direction of migration depends on the nature of the exact interaction.  If the binding of the 
antibody and the probe to the TF is “cooperative”—that is, if the two bind to different 
sites on the TF—the entire complex would be larger than the shift complex and would 
migrate relatively higher on the gel.  If the binding of the antibody and the probe is 
“competitive,” i.e. the two attempt to bind at the same site on the TF, the addition of the 
antibody would result in more unbound labeled probe than in the shift step, and a strong 
band would reappear at the bottom of the gel.  The details of this assay are shown in 
Figure 10, next page. 
Our results identified a competitive interaction between anti-PEA3 and probe 1 
from BV677278.  Adding an increasing amount of anti-PEA3 to the mixture of probe and 
lysate produced an increasingly intense band at the bottom of the gel (seen in lanes 4-7 of 
figure 2).  Reactions using either a control probe (DNA encoding the Epstein-Barr 
Nuclear Antigen, EBNA) or control antibody (human anti-Oct2a) showed the same 
pattern as that seen with probe and nuclear lysate only, implying that the interaction 
between anti-PEA3 and the target antigen was specific.  The fact that only the 
combination of the experimental probe, nuclear lysate, and anti-PEA3 created supershift 
implies that the target antigen for the probe is, in fact, PEA3.  
 One problem with the supershift assay is its artificiality.  Manipulating the 
parameters of the binding reaction—changing the pH, adding monovalent and divalent 
ions, raising or lowering the reaction temperature—affect the binding avidity of the 
components.47  In this case, adding glycerol and potassium and incubating the antibody 
with the lysate for two hours before adding the labeled probe produced supershift, while 
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other sets of reaction conditions did not.  Given the delicacy of this interaction, it is 
unclear how applicable these results are to understanding how PEA3 and BV677278 
actually interact in a physiologic system.
   
 
 
Figure 10.  Details of EMSA supershift assays.  A. When labeled probe is incubated alone, its high mobility leads to a band at the bottom of the gel.                
B. When probe interacts with lysate (green arrow), the mobility of the complex is much lower than probe alone, and a large band appears higher on the gel.     
C. If antibody specific to the correct transcription factor is added, and if this antibody binds the factor at different site than the probe (green arrows), the entire 
complex will have greatly reduced mobility and a very large band will appear at the top of the gel.  D. If the antibody and probe bind at the same site (red 
arrows), the competition for binding will lead to an increase in the amount of unbound labeled probe, restoring the small band at the bottom of the gel.  Because 
some probe will also bind the lysate, a larger band of high molecular weight will usually remain. 
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In addition, an ideal experiment would have shown supershift using all four probes, since 
all four contain the canonical binding site for PEA3.  Unfortunately, human brain nuclear 
lysate is relatively difficult to come by, and our supplier quit stocking it shortly after we 
had completed the assay with probe 1.  Although there are other suppliers selling similar 
product, we would ideally use lysate from the same lot for all experiments, to control for 
variation in lysate contents due to genetic heterogeneity of the donors.   
 More physiologic assays than the EMSA exist.  One would be a Chromatin 
ImmunoPrecipitation (ChIP), which, unfortunately, limited time did not allow us to 
perform.  In a ChIP, the chromatin of a cell population is cross-linked, usually with 
formaldehyde, to preserve all bound transcription factors, and the cells are lysed.  The 
chromatin-TF mixture is then applied to a bead matrix on which has been fixed an 
antibody to the target antigen (e.g. PEA3).  After the pull-down, the crosslinking is 
reversed and the recovered DNA is subjected to PCR with the appropriate primers (e.g., 
to BV677278 or fragments thereof).48  A successful ChIP using this strategy would show 
not only that BV677278 and PEA3 can bind to each other under artificial conditions, but 
that they actually are bound to each other in live cells.  Completing this assay would 
require careful selection of an appropriate cell line (e.g. neurons or neuronal precursors), 
since the interaction is likely tissue-specific.  Furthermore, since the relationship may be 
temporally specific, it may be necessary to study differentiating cells at distinct time 
points, or to use primary cells harvested from animals of different ages.   
 After addressing the question of binding, we turned to the second question—
whether PEA3 expression affects that of either DCDC2 or KIAA0319—by asking the 
inverse: if PEA3 expression is abolished, does the expression of either target gene 
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change?  We identified at least two ways to abolish PEA3 expression.  The first, 
described by Hasegawa et al in 2005, would be to engineer an expression vector that 
produces only the DNA-binding portion of PEA3, but not the functional domain.  The 
product of such a vector would thus compete directly with wildtype PEA3 for binding to 
target sites, but would be essentially non-functional.  If produced in saturating quantities 
(for instance, under a constitutive promoter), the non-functional PEA3 would block 
almost all wildtype protein from binding, effectively abolishing its function. 
 The other strategy would be to use small inhibitor RNAs (siRNA, also known as 
RNAi knockdown), to prevent PEA3 RNA from being translated into protein.  In this 
technique, an siRNA containing a sequence complementary to a specific region of the 
target RNA is transfected into cells and, after binding its target, signals the cells to 
degrade the entire complex.49, 50  One potential drawback to using siRNA to specifically 
block the production of transcription factors is that some TFs are “pre-manufactured” in 
large quantities and stored within the nucleus until needed.51  If this were the case with 
our target TF, blocking the translation of RNA to protein would not affect the molecules 
of TF that have already been produced.  On the other hand, the technique is relatively 
easy, as commercially produced anti-PEA3 siRNA is readily available, whereas the 
production of a dominant negative vector like that described above would take several 
months of molecular genetics.  Thus, we elected to try the siRNA approach first. 
 We also needed to find an appropriate biologic model, since we cannot easily 
analyze the molecular interactions of the developing human brain.  Because PEA3, 
DCDC2, and KIAA0319 are all highly conserved, we decided it would be acceptable to 
begin our studies in cells derived from lower mammals, e.g. mice or rats.  However, since 
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we were interested in neural-specific interactions, we reasoned that we would need to 
study neural cell lines.  Furthermore, these interactions presumably change during the 
course of brain development, so we would need to use a cell line that can differentiate 
from immature precursors into mature neurons.  We chose cell lines for this purpose: 
mouse embryonic stem cells (mESCs)52 and P19 cells, a line derived from a mouse 
embryonal carcinoma.35, 53  The mESCs unfortunately yielded very small amounts for 
RNA and protein and were thus not well suited for our purposes.  The data presented here 
thus come from P19s. 
Our results from the siRNA knockdown of PEA3 mRNA in P19s imply a 
relationship between PEA3 and DCDC2 in early neural development.  A similar 
relationship was not seen between PEA3 and KIAA0319.  Before discussing these results 
in detail, it is important to note that the protocol for differentiating P19s into neural-like 
cells utilizes all-trans-retinoic acid (atRA), which is somewhat toxic to the cells and 
causes them to apoptose after several days of exposure.  This may explain why the 
siRNA was only effective at knocking down PEA3 early in the differentiation timeline 
(i.e. days 0 and 1), but not at days 5 and 6.  
 Wildtype P19 cells initially express DCDC2 at low levels.  Upon exposure to 
atRA and the initiation of neural differentiation, DCDC2 levels surge, reaching a peak at 
day 2 and returning to baseline by day 6 (a timepoint roughly analogous to late neural 
development in an animal model).  The introduction of anti-PEA3 siRNA appears to 
delay this surge and decline until later in neural development.  On the other hand, there is 
no such effect on KIAA0319 expression, which in both wildtype and PEA3 knockdown 
cells remains low during early development and rises around day 5.  One plausible 
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explanation for the lack of relationship between PEA3 and KIAA0319 is that the mouse 
KIAA0319 ortholog is located on a different chromosome than mouse DCDC2.  This is 
quite different than the location of their human counterparts, which lie in very close 
proximity on chromosome 6 within the same dyslexia locus.  If a later study were to 
show a regulatory relationship between PEA3 and KIAA0319 in humans, this finding 
might imply the migration of KIAA0319 into the vicinity of a new regulatory complex, 
which could arguably have contributed to the development of higher cognitive functions 
like reading. 
 The exact nature of the relationship between DCDC2 and PEA3 is not clear from 
these experiments.  Knocking down PEA3 in P19 cells appears to delay the surge in 
DCDC2 expression by about two to three days in the atRA differentiation timeline.  
Furthermore, to achieve this change in DCDC2 expression, it is sufficient to knock down 
PEA3 only in the first two days of differentiation.  This implies that PEA3 normally plays 
some role in DCDC2’s upregulation and that, since the effect of knocking down PEA3 
mRNA is not immediate, the interaction between the two must either be indirect or take 
some time to manifest even under normal circumstances. 
 These results must be interpreted with caution and will require more complex 
physiologic studies to support them.   In this study, the baseline gene expression of 
wildtype P19 cells is used as a negative control.  To say with certainty that the effect on 
DCDC2 expression is truly due to the knockdown of PEA3, however, one would like to 
see that cells transfected with a “dummy” siRNA, containing scrambled sequences that 
are not complimentary to any known RNA sequence, express DCDC2 similarly to 
wildtype cells.  We began our experiments with such a control, but the cells transfected 
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with that construct died early and yielded insufficient RNA for RT-PCR.  Ideally, this 
entire experiment should be repeated, with the use of scrambled siRNA, rather than 
wildtype cells, as a negative control. 
 Although interrogation of interactions between a transcription factor and target 
genes by siRNA knockdown, termed “pathway studies,” has precedent in the current 
literature, the specifics of our approach appear to be novel; we were unable to identify a 
study that examined the effect of TF knockdown on a handful of candidate genes during 
the course of tissue development.  One recently published study, for instance, examined 
the effect of knocking down NPAS2, a TF that has been identified as a potential tumor 
suppressor, on the expression of genes known to repair DNA damage.54  The study used 
techniques of siRNA transfection and qRT-PCR analysis similar to ours, but the authors 
also utilized gene chip technology to observe changes in the expression of thousands of 
genes, rather than the two targets our study identified.  Other recent examples of pathway 
studies are similarly broad in scope.55  
 Examples of pathway studies with a narrower focus exist in the current literature 
as well, but many treat the interaction of transcription factor and targeted gene as a 
binary, on-off proposition, isolated in space and time.  One recent study, for example, 
explored the relationship of the transcription factor PU.1 on the expression of a pathogen 
receptor gene, LSECtin, in human Kupffer cells.56 The authors found that knockdown of 
PU.1 in Kupffer cells decreased LSECtin expression, which they felt showed a regulatory 
relationship between the two elements.  Unlike our paradigm, this relationship was 
assumed to be immediate and was not assessed in the context of developing tissue.  
Several other examples of such studies can be found in the literature as well.57, 58 
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 Finally, perhaps the broadest group of pathway studies examines the effect of 
transcription factor knockdown not on the expression of target genes, but on phenotypes.  
A recent study in MLL-fusion leukemia cells, for instance, showed that knockdown of 
the homeobox gene Meis1 inhibited tumor growth.59  Another study of neurogenesis in 
mice showed that knockdown of the transcription factors COUP-TFI and II prolonged the 
ability of embryos to generate new neurons.60  The observation of a relationship between 
a transcription factor and a phenotype is valuable, but these studies are generally only the 
first step towards understanding the underlying mechanism behind this relationship, and 
further studies to identify intermediate effector genes will always be necessary to 
elucidate the entire pathway. 
 The value of our approach is twofold.  First, it provides evidence for a pathway 
connecting PEA3 and an observed phenotype, aberrant neuronal migration, by examining 
the regulatory effect of PEA3 on a downstream gene, DCDC2.  Although the details of 
the pathway are not yet fully understood (mainly, how does DCDC2 affect neuronal 
migration at a molecular level?), these data begin to outline a rough framework on which 
the rest of the pathway may be based.  Second, our approach appears to be novel in that it 
examines the effect of a transcription factor over the course of cell development and 
differentiation, not at a static point in space and time.  Despite the limitations of our 
system, such an approach may be more physiologic than those employed by other studies, 
given its recognition that interactions within genetic regulatory networks are dynamic, 
and that perturbations in the networks may not have an immediately observable effect.  
Overall, our results imply that both normal expression PEA3, and a normal early surge in 
DCDC2, are necessary for normal neuronal migration, and that decreased expression of 
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either element is sufficient to distort the process (Figure 11, below).  In particular, we 
emphasize our hypothesis that decreased PEA3 expression leads to aberrant migration 
through a delay in the DCDC2 surge. 
 
Figure 11.  Proposed pathway linking PEA3, DCDC2, and neuronal migration.  A: Both high early 
expression of PEA3 and a normal early surge of DCDC2 expression, as seen in wildtype P19s, are 
necessary for normal neural migration to the outer layers of cortex.  B: Either decreased early levels of 
PEA3 or delay of DCDC2 surge is sufficient to distort neural migration and cause progenitors to arrest in 
the intermediate zone of the brain. 
            
 The results of this study imply the potential for more complex studies in an 
animal model.   Such a study might begin by replicating the experiments of Hasegawa et 
al to show a migration defect in neural progenitors that have been transfected with a 
dominant-negative mutation for PEA3.  The experiment would continue on to determine 
whether the same migration deficit can be replicated by knocking out the BV677278 
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region from implanted cells so that, presumably, PEA3 would be unable to bind DCDC2 
at this location.  Finally, one would have to determine whether the migration deficit 
observed in PEA3-negative cells can be mitigated by the overexpression of DCDC2 
through the transfection of an expression vector under a strong promoter.  This would be 
a complex and involved experiment that would require expertise in both molecular 
genetics (for the development of the PEA3-negative vector and the overexpression 
vectors) and animal experiments (for the implantation of transfected cells into the brains 
of fetal mice or rats).   
Overall, these experiments imply that our hypothesis was correct.  BV677278 
appears to be a critical regulatory element for DCDC2.  This effect appears to be 
modulated by PEA3, which binds BV677278 and increases the expression of DCDC2, 
with little evidence to suggest that, at least in mouse cells, it affects the expression of 
KIAA0319.  Further experiments are necessary to confirm this and to prove, by extension, 
that gene regulation governed by PEA3 is in part responsible for aspects of brain 
development that regulate reading ability.  One day, confirming these types of 
relationships between genotype and phenotype may enable us to identify children at risk 
of becoming poor readers and to institute early educational interventions that can improve 
their performance before they fall behind their normal-reading peers.  Before this can 
occur, however, we need a more well-founded and complete understanding of these 
interactions, which will further our comprehension of the underlying genetic structure of 
reading. 
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Appendix 1. Transcription Factors returned by TESS Search  
 
(Transcription Element Search Software: http:// www.cbil.upenn.edu/cgi-bin/tess/tess?RQ=WELCOME) 
 
Nucleic Acid Codes: A, Adenine; G, Guanine; T, Thymine; C, Cytosine; Y, Pyrimidine (T/C); R, Purine (A/G); M, A/C; S, C/G; W, A/T; 
N, any.  
 
Factor Consensus Sequence Known Species Known Tissue Molecular Function 
PEA3 AGGAAR Human, mouse, rat, pig Brain, epidermis, lung Interacts with oncogenes 
NF-1 TGGCA Human; Adenovirus Ubiquitous Enhances viral 
replication 
TCF-1 MAMAG Human T cells, intestinal and 
mammary epithelia 
Multiple downstream 
targets in T-cells 
LEF-1 MAMAG Human, many T-cells Member of Wnt cascade 
c-ETS-1 SMGGAWGY Human, mouse, chick, 
xenopus 
T-cells Unknown; levels highest 
in resting T-cells 
   
Factor Consensus Sequence Known Species Known Tissue Molecular Function 
YY1 SSGCCATCTTSNCTS Human, mouse Skeletal Muscle, other? Catecholamine 
synthesis? 
Elf-1 GAAGAGGAAAAA Humans, Mouse Lymphoid Unknown; expressed in 
activated T-cells 
PU.1 AGAGGAACT Human, Mouse, Chick, 
Yeast 
Lymphoid, Liver, Testes Interferes with 
erythroblast maturation 
NP-TCII ANANTTTCC Human, Mouse Lymphoid Unknown 
GT-IIA AGCTGGTTCTTTCC Human HeLa, Molt-4, BJA-B Unknown 
GAL4 CGGAGGACAGTACTCCG Yeast Yeast Mediates galactose 
response 
Dof2 AAAG Maize Leaves Promoter-specific 
actions 
   
Factor Consensus Sequence Known Species Known Tissue Molecular Function 
MNB1a AAAG Maize Leaves, stems, roots Promoter-specific 
actions 
Delta Factor SSGCCATCTTSNCTS Mouse Brain Activates ribosomal 
genes 
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Appendix 2 
 
 
Notes on Conventions and List of Abbreviations 
 
By convention, gene names and mRNA transcripts are listed in italics.  Protein names, 
even if the same as gene names, are not italicized.  Human genes and proteins are 
capitalized, whereas mouse genes and proteins are in lower case.  In some cases, human 
genes and their mouse orthologs have different official names; in these cases, this 
difference is noted, but the mouse ortholog is referred to by the human name to avoid 
confusion. 
 
Genes, Proteins, and Regions 
1. DCDC2: Candidate gene for dyslexia, on 6p22 in the DYX2 locus. 
2. KIAA0319: Another candidate gene for dyslexia, on 6p22 in the DYX2 locus. 
3. BV677278: an approximately 600-bp region in intron 2 of DCDC2, hypothesized 
to have regulatory activity related to the development of dyslexia. 
4. PEA3: a member of the ETS family of transcription factors.  Previously shown to 
be involved in oncogenesis and neuronal migration. 
5. DYX1C1: A candidate gene for dyslexia, on 15q11 in the DYX1 locus. 
6. ROBO1:  A candidate gene for dyslexia on 3p12 in the DYX5 locus. 
7. DYX loci: regions shown to be in linkage with dyslexia (10 total). 
 
Abbreviations and Terms 
1. atRA: all-trans-retinoic acid, used to differentiate P19s into neuron-like cells. 
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2. Knockdown: inhibition of mRNA transcripts using siRNA (blocks RNA to 
protein translation). 
3. Knockout: inhibition of gene through targeted deletion (blocks gene to RNA 
transcription). 
4. P19: mouse embryonal carcinoma cell line. 
5. RD: Reading Disability, also known as developmental dyslexia. 
6. siRNA: small inhibitory RNA.  Used to knock down mRNA transcripts  
7. SNP: single nucleotide polymorphism, the most common type of marker used in 
modern genetic linkage and association studies. 
8. TF: transcription factor 
 
